BRPI0912384A2 - composição, e, método para preparar uma composição - Google Patents

composição, e, método para preparar uma composição

Info

Publication number
BRPI0912384A2
BRPI0912384A2 BRPI0912384A BRPI0912384A BRPI0912384A2 BR PI0912384 A2 BRPI0912384 A2 BR PI0912384A2 BR PI0912384 A BRPI0912384 A BR PI0912384A BR PI0912384 A BRPI0912384 A BR PI0912384A BR PI0912384 A2 BRPI0912384 A2 BR PI0912384A2
Authority
BR
Brazil
Prior art keywords
composition
preparing
Prior art date
Application number
BRPI0912384A
Other languages
English (en)
Inventor
Thomas W Leonard
Original Assignee
Merrion Res Iii Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merrion Res Iii Ltd filed Critical Merrion Res Iii Ltd
Publication of BRPI0912384A2 publication Critical patent/BRPI0912384A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/03—Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/16—Masculine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gynecology & Obstetrics (AREA)
  • Emergency Medicine (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
BRPI0912384A 2008-05-07 2009-05-07 composição, e, método para preparar uma composição BRPI0912384A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5103808P 2008-05-07 2008-05-07
PCT/US2009/002842 WO2009137078A1 (en) 2008-05-07 2009-05-07 Compositions of peptides and processes of preparation thereof

Publications (1)

Publication Number Publication Date
BRPI0912384A2 true BRPI0912384A2 (pt) 2015-10-13

Family

ID=40801968

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0912384A BRPI0912384A2 (pt) 2008-05-07 2009-05-07 composição, e, método para preparar uma composição

Country Status (13)

Country Link
US (3) US20090280169A1 (pt)
EP (2) EP2288369B1 (pt)
JP (4) JP5671451B2 (pt)
KR (2) KR20110007614A (pt)
CN (3) CN102046192B (pt)
AU (2) AU2009244799B2 (pt)
BR (1) BRPI0912384A2 (pt)
CA (2) CA2723541A1 (pt)
IL (1) IL209136A (pt)
MX (1) MX2010012201A (pt)
RU (1) RU2517135C2 (pt)
TW (2) TW200950801A (pt)
WO (2) WO2009137078A1 (pt)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8119159B2 (en) * 1999-02-22 2012-02-21 Merrion Research Iii Limited Solid oral dosage form containing an enhancer
US20070148228A1 (en) * 1999-02-22 2007-06-28 Merrion Research I Limited Solid oral dosage form containing an enhancer
US7658938B2 (en) * 1999-02-22 2010-02-09 Merrion Reasearch III Limited Solid oral dosage form containing an enhancer
US20070219131A1 (en) * 2004-04-15 2007-09-20 Ben-Sasson Shmuel A Compositions capable of facilitating penetration across a biological barrier
CA2563533C (en) * 2004-04-15 2013-10-01 Shmuel A. Ben-Sasson Compositions capable of facilitating penetration across a biological barrier
BRPI0710503A2 (pt) 2006-04-07 2011-08-16 Merrion Res Iii Ltd uso de uma composição farmacêutica, composição farmacêutica, e, forma de dosagem oral
US20090280169A1 (en) * 2008-05-07 2009-11-12 Merrion Research Iii Limited Compositions of peptides and processes of preparation thereof
RU2678833C2 (ru) 2008-09-17 2019-02-04 Киазма Инк. Фармацевтические композиции и соответствующие способы доставки
US9089484B2 (en) 2010-03-26 2015-07-28 Merrion Research Iii Limited Pharmaceutical compositions of selective factor Xa inhibitors for oral administration
AU2011341637A1 (en) * 2010-12-15 2013-06-20 Merrion Research Iii Limited Pharmaceutical compositions of selective factor Xa inhibitors for oral administration
EP2661273A4 (en) 2011-01-07 2014-06-04 Merrion Res Iii Ltd IRON PHARMACEUTICAL COMPOSITIONS FOR ORAL ADMINISTRATION
KR102140982B1 (ko) * 2012-06-01 2020-08-05 훼링 비.브이. 데가렐릭스의 제조 방법
UA116217C2 (uk) 2012-10-09 2018-02-26 Санофі Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
HUE035803T2 (en) 2012-12-21 2018-05-28 Sanofi Sa Dual GLP1 / GIP or trigonal GLP1 / GIP / glucagon agonists
CN104072603B (zh) * 2013-03-27 2017-09-05 深圳翰宇药业股份有限公司 一种合成替度鲁肽的方法
CN104072605B (zh) * 2013-03-27 2017-03-29 深圳翰宇药业股份有限公司 一种替度鲁肽的制备方法
TW201609797A (zh) 2013-12-13 2016-03-16 賽諾菲公司 雙重ｇｌｐ－１／升糖素受體促效劑
WO2015086730A1 (en) 2013-12-13 2015-06-18 Sanofi Non-acylated exendin-4 peptide analogues
WO2015086728A1 (en) 2013-12-13 2015-06-18 Sanofi Exendin-4 peptide analogues as dual glp-1/gip receptor agonists
EP3080154B1 (en) 2013-12-13 2018-02-07 Sanofi Dual glp-1/gip receptor agonists
TW201625668A (zh) 2014-04-07 2016-07-16 賽諾菲公司 作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物
TW201625669A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑
TW201625670A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑
JP6672175B2 (ja) * 2014-05-07 2020-03-25 ノヴォ ノルディスク アー／エス Ｇｌｐ−１及び抗ｉｌ−２１を使用した１型糖尿病の治療
US9932381B2 (en) 2014-06-18 2018-04-03 Sanofi Exendin-4 derivatives as selective glucagon receptor agonists
CN105636937B (zh) * 2015-01-27 2018-07-17 深圳华大生命科学研究院 用于保存生物样品的稳定剂
JP7211704B2 (ja) * 2015-01-29 2023-01-24 ノヴォ ノルディスク アー／エス Ｇｌｐ－１アゴニスト及び腸溶コーティングを含む錠剤
US9937223B2 (en) 2015-01-30 2018-04-10 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9744209B2 (en) 2015-01-30 2017-08-29 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9375478B1 (en) 2015-01-30 2016-06-28 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9687526B2 (en) 2015-01-30 2017-06-27 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9750785B2 (en) 2015-01-30 2017-09-05 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9925233B2 (en) 2015-01-30 2018-03-27 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
SI3253401T1 (sl) 2015-02-03 2025-07-31 Amryt Endo, Inc. Zdravljenje akromegalije z oralnim oktreotidom
AR105319A1 (es) 2015-06-05 2017-09-27 Sanofi Sa Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
CN104998251A (zh) * 2015-07-08 2015-10-28 哈尔滨吉象隆生物技术有限公司 用于口服肠溶制剂制备的具有促肠吸收作用的利拉鲁肽盐
TW201706291A (zh) 2015-07-10 2017-02-16 賽諾菲公司 作為選擇性肽雙重ｇｌｐ－１／升糖素受體促效劑之新毒蜥外泌肽（ｅｘｅｎｄｉｎ－４）衍生物
CN105749245A (zh) * 2016-03-02 2016-07-13 张光泉 抗癌药醋酸地加瑞克注射液及其制备方法
KR101786914B1 (ko) * 2017-01-31 2017-11-15 주식회사 삼양사 피부 리프팅 또는 탄력 개선을 위한 점착성 탄력 밴드
JP6901801B2 (ja) * 2017-06-14 2021-07-14 バイオソリューション カンパニー・リミテッドＢｉｏ Ｓｏｌｕｔｉｏｎ Ｃｏ Ｌｔｄ 物質ｐを含むしわの改善または抗炎症化粧料組成物
SG11202000881VA (en) * 2017-08-01 2020-02-27 Fund Sa Adjuvant therapy for use in prostate cancer treatment
CN107412739B (zh) * 2017-08-09 2020-02-07 南通大学 IFN-λ在Zika病毒感染中的新用途
SG11202001436YA (en) 2017-08-18 2020-03-30 Abbvie Inc Pharmaceutical formulations for treating endometriosis, uterine fibroids, polycystic ovary syndrome or adenomyosis
CA3073247A1 (en) * 2017-08-18 2019-02-21 Abbvie Inc. Solid pharmaceutical formulations for treating endometriosis, uterine fibroids, polycystic ovary syndrome and adenomyosis
TW201919632A (zh) * 2017-08-18 2019-06-01 美商艾伯維有限公司 治療子宮內膜異位症、子宮纖維瘤、多囊性卵巢症候群或子宮腺肌症之醫藥調配物
TW201912157A (zh) * 2017-08-18 2019-04-01 美商艾伯維有限公司 治療子宮內膜異位症、子宮纖維瘤、多囊性卵巢症候群及子宮腺肌症之固體醫藥調配物
CN107952063A (zh) * 2017-12-27 2018-04-24 北京四环生物制药有限公司 降钙素片及其制备方法
US11690854B2 (en) 2018-04-19 2023-07-04 Abbvie Inc. Methods of treating heavy menstrual bleeding
CN109400700A (zh) * 2018-11-06 2019-03-01 安徽怡发生物科技有限公司 一种易吸收的胶原蛋白低聚肽的制备方法
CN111265654B (zh) * 2018-12-05 2023-05-16 江苏恒瑞医药股份有限公司 Glp-1类似物的药物组合物及其制备方法
WO2021180862A1 (en) 2020-03-12 2021-09-16 Synthon B.V. Pharmaceutical compositions comprising elagolix sodium
US11141457B1 (en) 2020-12-28 2021-10-12 Amryt Endo, Inc. Oral octreotide therapy and contraceptive methods
CN117247422A (zh) * 2022-12-06 2023-12-19 杭州先为达生物科技股份有限公司 一种多肽衍生物及其制备方法

Family Cites Families (175)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US599432A (en) * 1898-02-22 Wagon-jack
US3010A (en) * 1843-03-21 Iiziiiiijiiii
GB953626A (en) 1961-04-25 1964-03-25 Meito Sangyo Kk Enteric-coated tablets of dextran sulphate ester and method of preparation thereof
US4900730A (en) 1981-01-14 1990-02-13 Toyo Jozo Co., Ltd. Preparation which promotes the absorption of peptides
JPS57146722A (en) 1981-03-06 1982-09-10 Toyo Jozo Co Ltd Pharmaceutical preparation having improved absorption
US4525339A (en) 1982-10-15 1985-06-25 Hoffmann-La Roche Inc. Enteric coated oral dosage form
JPS5973600A (ja) 1982-10-19 1984-04-25 Okayasu Shoten:Kk 排卵誘発剤
WO1984004674A1 (en) 1983-05-31 1984-12-06 Jang Choong Gook Dry direct compression compositions for controlled release dosage forms
DE3331009A1 (de) * 1983-08-27 1985-03-14 Basf Ag, 6700 Ludwigshafen Verfahren zur erhoehung der enteralen resorbierbarkeit von heparin bzw. heparinoiden sowie das so erhaeltliche heparin- bzw. heparinoidpraeparat
US4590062A (en) * 1984-04-16 1986-05-20 Tech Trade Corp. Dry direct compression compositions for controlled release dosage forms
US4654155A (en) 1985-03-29 1987-03-31 Reynolds Metals Company Microemulsion lubricant
US5288497A (en) 1985-05-01 1994-02-22 The University Of Utah Compositions of oral dissolvable medicaments
US4764375A (en) 1985-09-11 1988-08-16 Kv Pharmaceutical Company Sachet drug delivery system
CH667994A5 (de) 1986-05-27 1988-11-30 Sandoz Ag Pharmazeutische zusammensetzungen mit polypeptid-wirkstoffen.
US4786508A (en) 1986-05-30 1988-11-22 Warner-Lambert Company Coated dosage forms
US4789547A (en) 1987-06-17 1988-12-06 Warner-Lambert Company Transdermal matrix system
IL87710A (en) 1987-09-18 1992-06-21 Ciba Geigy Ag Covered floating retard form for controlled release in gastric juice
US5221734A (en) * 1987-10-01 1993-06-22 Ciba-Geigy Corporation Process for preparing a polypeptide growth factor for milk
GB2212396A (en) 1987-12-18 1989-07-26 Procter & Gamble Dietary supplement comprising calcium and delayed release coated iron
NZ228285A (en) 1988-03-11 1991-08-27 Teikoku Seiyaku Kk Pharmaceutical composition comprising a polypeptide and adapted for intravaginal administration
US5169933A (en) 1988-08-15 1992-12-08 Neorx Corporation Covalently-linked complexes and methods for enhanced cytotoxicity and imaging
US5190748A (en) * 1988-11-22 1993-03-02 Hoffmann-La Roche Inc. Absorption enhancement of antibiotics
ZA898331B (en) 1988-11-22 1990-07-25 Hoffmann La Roche Pharmaceutical compositions
IL92537A (en) 1988-12-15 1994-04-12 Riker Laboratories Inc Topical preparations and dermal systems containing 1-isobutyl-H1-imidazo [C-4,5] quinoline-4-amine
JP3009911B2 (ja) * 1989-06-28 2000-02-14 エーザイ株式会社 ペプチド又は蛋白の内服用新規製剤
GB2244015B (en) 1990-03-14 1993-10-27 Hadley Sections Limited Tube and method of forming same
JPH03275633A (ja) 1990-03-23 1991-12-06 Teikoku Seiyaku Co Ltd 生理活性ポリペプチドの吸収促進剤
US5541155A (en) 1994-04-22 1996-07-30 Emisphere Technologies, Inc. Acids and acid salts and their use in delivery systems
JPH04149126A (ja) 1990-10-09 1992-05-22 Mitsubishi Kasei Corp 経粘膜投与用医薬組成物
US5110606A (en) * 1990-11-13 1992-05-05 Affinity Biotech, Inc. Non-aqueous microemulsions for drug delivery
IT1245761B (it) 1991-01-30 1994-10-14 Alfa Wassermann Spa Formulazioni farmaceutiche contenenti glicosaminoglicani assorbibili per via orale.
US5744450A (en) 1991-03-14 1998-04-28 The Salk Institute For Biological Studies GnRH analogs
US5688761A (en) 1991-04-19 1997-11-18 Lds Technologies, Inc. Convertible microemulsion formulations
DE69229779T2 (de) 1991-04-19 1999-12-23 Lds Technologies, Inc. Konvertierbare mikroemulsionsverbindungen
CA2070061C (en) 1991-06-07 2004-02-10 Shigeyuki Takama Physiologically active polypeptide-containing pharmaceutical composition
CZ282760B6 (cs) 1991-11-22 1997-09-17 Procter And Gamble Pharmaceuticals, Inc. Risedronátové prostředky se zpožděným uvolňováním
US5206219A (en) * 1991-11-25 1993-04-27 Applied Analytical Industries, Inc. Oral compositions of proteinaceous medicaments
US5229130A (en) 1991-12-20 1993-07-20 Cygnus Therapeutics Systems Vegetable oil-based skin permeation enhancer compositions, and associated methods and systems
SE501389C2 (sv) 1992-04-24 1995-01-30 Leiras Oy Farmaceutiskt preparat och förfarande för dess framställning
US5229103A (en) * 1992-04-30 1993-07-20 Hydrodent Laboratories, Inc. Antiplaque mouthwash concentrate
DE4317458A1 (de) * 1992-06-11 1993-12-16 Bayer Ag Verwendung von cyclischen Depsipeptiden mit 18 Ringatomen zur Bekämpfung von Endoparasiten, neue cyclische Depsipeptide mit 18 Ringatomen und Verfahren zu ihrer Herstellung
JP3190441B2 (ja) 1992-07-20 2001-07-23 エーザイ株式会社 塩酸アゼラスチンを含有する安定な製剤
RU2068689C1 (ru) 1992-09-24 1996-11-10 Товарищество с ограниченной ответственностью "Лекрон" Способ получения таблеток парацетамола
WO1994008599A1 (en) * 1992-10-14 1994-04-28 The Regents Of The University Of Colorado Ion-pairing of drugs for improved efficacy and delivery
KR0157280B1 (ko) 1992-11-06 1998-11-16 나까토미 히로타카 하부소화관 방출성의 경구의약제제
JPH06192107A (ja) 1992-12-25 1994-07-12 Sanwa Kagaku Kenkyusho Co Ltd グリチルリチン経口剤
US5346701A (en) 1993-02-22 1994-09-13 Theratech, Inc. Transmucosal delivery of macromolecular drugs
SE9302135D0 (sv) * 1993-06-18 1993-06-18 Kabi Pharmacia Ab New pharmaceutical composition
TW402506B (en) 1993-06-24 2000-08-21 Astra Ab Therapeutic preparation for inhalation
US5633347A (en) * 1993-06-29 1997-05-27 University Of Utah Research Foundation Conotoxin peptides
ES2068762B1 (es) 1993-07-21 1995-12-01 Lipotec Sa Un nuevo preparado farmaceutico para mejorar la biodisponibilidad de drogas de dificil absorcion y procedimiento para su obtencion.
JPH09510182A (ja) * 1993-11-17 1997-10-14 エルディーエス・テクノロジーズ・インコーポレーテッド カプセル封入されたドラッグデリバリー用透明液
DE69530973T2 (de) 1994-02-16 2004-05-19 Abbott Laboratories, Abbott Park Verfahren zur herstellung feinteiliger pharmazeutischer formulierungen
US5506207A (en) * 1994-03-18 1996-04-09 The Salk Institute For Biological Studies GNRH antagonists XIII
ATE226090T1 (de) * 1994-04-22 2002-11-15 Yamanouchi Pharma Co Ltd Kolon-spezifisches arzneistofffreisetzungssystem
US5639469A (en) 1994-06-15 1997-06-17 Minnesota Mining And Manufacturing Company Transmucosal delivery system
IL110024A (en) 1994-06-15 1998-04-05 Yissum Res Dev Co Controlled release oral drug delivery system containing hydrogel- forming polymer
GB9414318D0 (en) * 1994-07-15 1994-09-07 Dowelanco Ltd Preparation of aqueous emulsions
AU713461B2 (en) 1994-11-17 1999-12-02 Toray Industries, Inc. Preparation for percutaneous absorption
US6524557B1 (en) * 1994-12-22 2003-02-25 Astrazeneca Ab Aerosol formulations of peptides and proteins
US5650386A (en) 1995-03-31 1997-07-22 Emisphere Technologies, Inc. Compositions for oral delivery of active agents
KR19990014865A (ko) 1995-05-17 1999-02-25 피터 이. 브래이브맨 소장에서의 소화 및 흡수를 증진시키기 위한, 지방산을 함유한조성물들
US6572879B1 (en) 1995-06-07 2003-06-03 Alza Corporation Formulations for transdermal delivery of pergolide
US5631347A (en) 1995-06-07 1997-05-20 Eli Lilly And Company Reducing gelation of a fatty acid-acylated protein
GB9516268D0 (en) 1995-08-08 1995-10-11 Danbiosyst Uk Compositiion for enhanced uptake of polar drugs from the colon
US5766620A (en) 1995-10-23 1998-06-16 Theratech, Inc. Buccal delivery of glucagon-like insulinotropic peptides
US5807983A (en) * 1995-12-28 1998-09-15 The Salk Institute For Biological Studies GNRH antagonist betides
DE69726879T2 (de) 1996-05-17 2004-10-14 Merck & Co., Inc. Biphosphonat-formulierung mit brausewirkung
US6147088A (en) 1996-05-20 2000-11-14 Merck & Co., Inc. Antagonists of gonadotropin releasing hormone
CA2254769A1 (en) 1996-05-20 1997-11-27 Merck & Co., Inc. Antagonists of gonadotropin releasing hormone
US6150522A (en) 1996-05-20 2000-11-21 Merck & Co., Inc. Antagonists of gonadotropin releasing hormone
US5932547A (en) * 1996-07-03 1999-08-03 Alza Corporation Non-aqueous polar aprotic peptide formulations
US5916582A (en) 1996-07-03 1999-06-29 Alza Corporation Aqueous formulations of peptides
GB9614235D0 (en) 1996-07-06 1996-09-04 Danbiosyst Uk Composition for enhanced uptake of polar drugs from mucosal surfaces
US5912009A (en) * 1996-10-30 1999-06-15 Theratech, Inc. Fatty acid esters of glycolic acid and its salts
US5925730A (en) 1997-04-11 1999-07-20 Ferring Bv GnRH antagonists
US5821230A (en) 1997-04-11 1998-10-13 Ferring Bv GnRH antagonist decapeptides
US6156767A (en) 1997-06-05 2000-12-05 Merck & Co., Inc. Antagonists of gonadotropin releasing hormone
US6156772A (en) 1997-06-05 2000-12-05 Merck & Co., Inc. Antagonists of gonadotropin releasing hormone
US6004984A (en) 1997-06-05 1999-12-21 Merck & Co., Inc. Antagonists of gonadotropin releasing hormone
US5981550A (en) * 1997-06-05 1999-11-09 Merck & Co., Inc. Antagonists of gonadotropin releasing hormone
WO1999001579A1 (en) 1997-07-01 1999-01-14 Isis Pharmaceuticals, Inc. Compositions and methods for the delivery of oligonucleotides via the alimentary canal
IL121269A0 (en) 1997-07-09 1998-01-04 Dpharm Ltd Compositions and methods for reversibly increasing permeability of biomembranes
IL121268A0 (en) 1997-07-09 1998-01-04 Dpharm Ltd Branched chain fatty acids their derivatives and use in the treatment of central nervous system disorders
JP4181232B2 (ja) 1997-07-18 2008-11-12 帝國製薬株式会社 ジクロフェナクナトリウム含有油性外用貼付製剤
US6015801A (en) 1997-07-22 2000-01-18 Merck & Co., Inc. Method for inhibiting bone resorption
SE9703691D0 (sv) 1997-10-10 1997-10-10 Astra Ab Pharmaceutical compositions
US6017944A (en) * 1997-10-28 2000-01-25 Merck & Co., Inc. Antagonists of gonadotropin releasing hormone
KR20010041696A (ko) 1998-03-11 2001-05-25 그레랑 파마수티컬 가부시키가이샤 발포성 장용(腸溶) 제제
US5998432A (en) 1998-04-02 1999-12-07 Merck & Co., Inc. Antagonists of gonadotropin releasing hormone
US6025366A (en) * 1998-04-02 2000-02-15 Merck & Co., Inc. Antagonists of gonadotropin releasing hormone
US6077847A (en) * 1998-04-02 2000-06-20 Merck & Co., Inc. Antagonists of gonadotropin releasing hormone
US6270804B1 (en) 1998-04-03 2001-08-07 Biovail Technologies Ltd. Sachet formulations
GB2336311A (en) 1998-04-15 1999-10-20 Merck & Co Inc Bisphosphonate Dosing Regimen
US6656922B2 (en) 1998-05-28 2003-12-02 Mediplex Corporation, Korea Oral delivery of macromolecules
JP3853985B2 (ja) 1998-08-03 2006-12-06 有限会社 健康百二十才 鉄イオン含有殺菌液
WO2000022909A2 (en) 1998-10-19 2000-04-27 Biotech Australia Pty. Limited Systems for oral delivery
US7658938B2 (en) * 1999-02-22 2010-02-09 Merrion Reasearch III Limited Solid oral dosage form containing an enhancer
US8119159B2 (en) 1999-02-22 2012-02-21 Merrion Research Iii Limited Solid oral dosage form containing an enhancer
DE60038097T2 (de) * 1999-02-22 2009-02-12 Merrion Research I Ltd. Feste orale dosierungsform enthaltend einen resorptionsverstärker
US20070148228A1 (en) 1999-02-22 2007-06-28 Merrion Research I Limited Solid oral dosage form containing an enhancer
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
SE9901272D0 (sv) 1999-04-09 1999-04-09 Astra Ab New improved formulation
JP2001081031A (ja) 1999-08-30 2001-03-27 Schering Ag 溶解性および経口吸収性を改善したベンズアミド誘導体含有製剤
EP1246839B1 (en) 1999-12-08 2004-06-16 Xcyte Therapies, Inc. Depsipeptide and congeners thereof for use as immunosuppressants
US20020002140A1 (en) * 2000-01-14 2002-01-03 Holick Michael F. Novel bisphosphonates and uses thereof
WO2001076577A2 (en) 2000-04-07 2001-10-18 The Board Of Regents Of The University Of Texas System Unique compositions of zwitterionic phospholipids and bisphosphonates and use of the compositions as bisphosphate delivery systems with reduced gi toxicity
US6468559B1 (en) 2000-04-28 2002-10-22 Lipocine, Inc. Enteric coated formulation of bishosphonic acid compounds and associated therapeutic methods
IT1318539B1 (it) * 2000-05-26 2003-08-27 Italfarmaco Spa Composizioni farmaceutiche a rilascio prolungato per lasomministrazione parenterale di sostanze idrofile biologicamente
CN1141974C (zh) * 2000-06-07 2004-03-17 张昊 结肠定位释放的口服生物制剂
DK1296689T3 (da) * 2000-06-20 2005-11-28 Novartis Ag Fremgangsmåde til indgivelse af bisphosphonater
WO2002055017A2 (en) * 2000-11-21 2002-07-18 Wake Forest University Method of treating autoimmune diseases
GB0029111D0 (en) 2000-11-29 2001-01-10 Novartis Ag Organic compounds
US6379960B1 (en) 2000-12-06 2002-04-30 Isis Pharmaceuticals, Inc. Antisense modulation of damage-specific DNA binding protein 2, p48 expression
US20020103131A1 (en) 2001-01-26 2002-08-01 Jacobson Jill D. Prevention of diabetes by administration of GnRH antagonists
JP2004525110A (ja) 2001-02-16 2004-08-19 清水製薬株式会社 ムコ多糖類製剤およびその製造法
CA2438848C (en) 2001-03-01 2011-05-03 Emisphere Technologies, Inc. Compositions for delivering bisphosphonates
BR0209365A (pt) * 2001-05-02 2004-06-08 Novartis Ag Usos farmacêuticos de bisfosfonatos
EP1390024A4 (en) 2001-05-11 2010-02-17 Merrion Res Iii Ltd ISOSTEARIC ACID SALTS AS PERMEATION IMPROVERS
ATE547095T1 (de) 2001-05-11 2012-03-15 Isis Pharmaceuticals Inc Antisense-permeationsverstärker
JP4381805B2 (ja) 2001-07-02 2009-12-09 メリオン リサーチ スリー リミテッド 生物活性材料の送達
US20030031757A1 (en) 2001-08-03 2003-02-13 Kraft Food Holdings, Inc. Stable and bioavailable iron fortified beverages
US7098305B2 (en) * 2001-09-06 2006-08-29 Ardana Bioscience Limited Sustained release of microcrystalline peptide suspensions
DE10157628A1 (de) 2001-11-26 2003-06-12 Zentaris Ag Injektionslösung eines LHRH-Antagonisten
US7214662B2 (en) * 2001-11-27 2007-05-08 Zentaris Gmbh Injectable solution of an LHRH antagonist
EP1460992B1 (en) * 2001-12-03 2009-03-11 Dor Biopharma, Inc. Stabilized reverse micelle compositions and uses thereof
JP2005516928A (ja) * 2001-12-13 2005-06-09 メルク　エンド　カムパニー　インコーポレーテッド 骨異常のためのビスホスホネート液体製剤
IL162293A0 (en) 2001-12-19 2005-11-20 Alza Corp Formulation and dosage form for increasing oral bioavailability of hydrophilic macromolecules
US7351800B2 (en) 2002-02-28 2008-04-01 Nipro Corporation Stabilized albumin preparations
US7148257B2 (en) * 2002-03-04 2006-12-12 Merck Hdac Research, Llc Methods of treating mesothelioma with suberoylanilide hydroxamic acid
BR0308901A (pt) * 2002-05-10 2005-01-04 Hoffmann La Roche ácidos bisfosfÈnicos para tratamento e prevenção de osteoporose
US7154002B1 (en) 2002-10-08 2006-12-26 Takeda San Diego, Inc. Histone deacetylase inhibitors
KR101152470B1 (ko) * 2003-08-13 2012-06-01 바이오콘 리미티드 치료제용 마이크로-입자 지방산 염 고형 투약 제형
US20050080075A1 (en) * 2003-08-25 2005-04-14 Nichols M. James Formulations, conjugates, and combinations of drugs for the treatment of neoplasms
AU2004273672A1 (en) 2003-09-19 2005-03-31 Wisconsin Alumni Research Foundation Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin D derivatives and a bisphosphonate
DE10345944B4 (de) * 2003-10-02 2007-06-21 Robert Bosch Gmbh Messfühler zur Bestimmung einer physikalischen Eigenschaft eines Gasgemisches
RU2006118801A (ru) 2003-10-31 2007-12-10 Алза Корпорейшн (Us) Композиции и лекарственные формы для усиления всасывания габапентина и прегабалина
US8987322B2 (en) 2003-11-04 2015-03-24 Circ Pharma Research And Development Limited Pharmaceutical formulations for carrier-mediated transport statins and uses thereof
DE10358525A1 (de) * 2003-12-13 2005-07-07 Bayer Healthcare Ag Endoparasitizide Mittel zur topischen Applikation
AR046773A1 (es) 2003-12-23 2005-12-21 Novartis Ag Formulaciones farmaceuticas de bisfosfonatos
AU2003290345A1 (en) 2003-12-24 2005-07-14 Astrazeneca Ab Pharmaceutical dissolution testing using a non-ionic surfactant
US7606313B2 (en) * 2004-01-15 2009-10-20 Ittiam Systems (P) Ltd. System, method, and apparatus for error concealment in coded video signals
WO2005072747A1 (ja) 2004-02-02 2005-08-11 Ono Pharmaceutical Co., Ltd. 骨吸収抑制剤
US20050249799A1 (en) * 2004-03-03 2005-11-10 Spherics, Inc. Polymeric drug delivery system for hydrophobic drugs
US20070219131A1 (en) * 2004-04-15 2007-09-20 Ben-Sasson Shmuel A Compositions capable of facilitating penetration across a biological barrier
CA2563533C (en) 2004-04-15 2013-10-01 Shmuel A. Ben-Sasson Compositions capable of facilitating penetration across a biological barrier
US20070212395A1 (en) * 2006-03-08 2007-09-13 Allergan, Inc. Ocular therapy using sirtuin-activating agents
KR20080083068A (ko) 2004-05-24 2008-09-12 더 프록터 앤드 갬블 캄파니 킬레이팅제를 함유하는 비스포스포네이트의 고형의 장용 경구 투여 형태
JP2006028031A (ja) * 2004-07-12 2006-02-02 Ltt Bio-Pharma Co Ltd 経粘膜吸収用薬物封入ナノ粒子
CA2574085C (en) * 2004-07-16 2014-02-11 Oakwood Laboratories, L.L.C. Gonadotropin releasing hormone antagonists
CN101027318B (zh) 2004-07-19 2016-05-25 比奥孔有限公司 胰岛素-低聚物共轭物，制剂及其用途
US20060078623A1 (en) * 2004-08-13 2006-04-13 Emisphere Technologies, Inc. Pharmaceutical formulations containing microparticles or nanoparticles of a delivery agent
JP4965446B2 (ja) * 2004-08-31 2012-07-04 ノヴォ ノルディスク アー／エス ペプチド、ポリペプチド及びタンパク質の安定化のためのトリス（ヒドロキシメチル）アミノメタンの使用
CN101056650A (zh) * 2004-11-12 2007-10-17 诺和诺德公司 促胰岛素肽的稳定制剂
EP1674082A1 (de) * 2004-12-22 2006-06-28 Zentaris GmbH Verfahren zur Herstellung von sterilen Suspensionen oder Lyophilisaten schwerlöslicher basischer Peptidkomplexe, diese enthaltende pharmazeutische Formulierungen sowie ihre Verwendung als Arzneimittel
WO2006102117A1 (en) 2005-03-17 2006-09-28 Elan Pharma International Limited Nanoparticulate biphosphonate compositions
TWI362392B (en) 2005-03-18 2012-04-21 Novo Nordisk As Acylated glp-1 compounds
IL174387A0 (en) 2005-03-31 2008-01-20 Dexcel Pharma Technologies Ltd A solid composition for intra-oral delivery of insulin
WO2006103657A2 (en) * 2005-03-31 2006-10-05 Dexcel Pharma Technologies Ltd. A solid composition for intra-oral delivery of insulin
WO2006116565A2 (en) 2005-04-25 2006-11-02 Amgen Inc. Biodegradable peptide sustained release compositions containing porogens
NZ580951A (en) 2005-04-29 2011-06-30 Cubist Pharm Inc Therapeutic compositions
JP2008542235A (ja) 2005-05-25 2008-11-27 ノボ・ノルデイスク・エー／エス 安定化ポリペプチド製剤
CN101505746A (zh) 2005-06-17 2009-08-12 迪纳米斯治疗公司 炎症的治疗方法
US20070021378A1 (en) 2005-07-22 2007-01-25 The Regents Of The University Of California Heparin compositions and selectin inhibition
US20070077313A1 (en) 2005-10-04 2007-04-05 U.S. Pharmaceutical Corporation Toleration iron supplement compositions
BRPI0710503A2 (pt) 2006-04-07 2011-08-16 Merrion Res Iii Ltd uso de uma composição farmacêutica, composição farmacêutica, e, forma de dosagem oral
US9283260B2 (en) 2006-04-21 2016-03-15 Amgen Inc. Lyophilized therapeutic peptibody formulations
WO2007146234A2 (en) 2006-06-09 2007-12-21 Merrion Research Ii Limited Solid oral dosage form containing an enhancer
US20090004281A1 (en) 2007-06-26 2009-01-01 Biovail Laboratories International S.R.L. Multiparticulate osmotic delivery system
CN101125132A (zh) 2007-07-25 2008-02-20 司炳奎 口服胰岛素肠溶胶囊及其制备方法
US20090280169A1 (en) 2008-05-07 2009-11-12 Merrion Research Iii Limited Compositions of peptides and processes of preparation thereof
RU2678833C2 (ru) * 2008-09-17 2019-02-04 Киазма Инк. Фармацевтические композиции и соответствующие способы доставки
TWI480286B (zh) 2009-02-25 2015-04-11 Merrion Res Iii Ltd 雙膦酸鹽類組合物及藥物遞送
US9089484B2 (en) 2010-03-26 2015-07-28 Merrion Research Iii Limited Pharmaceutical compositions of selective factor Xa inhibitors for oral administration
EP2661273A4 (en) 2011-01-07 2014-06-04 Merrion Res Iii Ltd IRON PHARMACEUTICAL COMPOSITIONS FOR ORAL ADMINISTRATION

Also Published As

Publication number Publication date
EP2288368A1 (en) 2011-03-02
MX2010012201A (es) 2011-05-30
US20090280170A1 (en) 2009-11-12
US8999383B2 (en) 2015-04-07
EP2288369A1 (en) 2011-03-02
EP2288369B1 (en) 2014-07-09
WO2009137080A1 (en) 2009-11-12
RU2010150093A (ru) 2012-06-20
AU2009244797A1 (en) 2009-11-12
AU2009244797B2 (en) 2015-01-22
CN107096012A (zh) 2017-08-29
TW200950799A (en) 2009-12-16
US20090280169A1 (en) 2009-11-12
CA2723541A1 (en) 2009-11-12
CN102046192A (zh) 2011-05-04
JP2011519928A (ja) 2011-07-14
IL209136A0 (en) 2011-01-31
TW200950801A (en) 2009-12-16
IL209136A (en) 2015-08-31
RU2517135C2 (ru) 2014-05-27
AU2009244799A1 (en) 2009-11-12
CN102046192B (zh) 2014-11-19
CN102056615A (zh) 2011-05-11
HK1157185A1 (en) 2012-06-29
JP5671451B2 (ja) 2015-02-18
JP2015155433A (ja) 2015-08-27
KR20110007614A (ko) 2011-01-24
JP2011519929A (ja) 2011-07-14
US20150238561A1 (en) 2015-08-27
WO2009137078A1 (en) 2009-11-12
AU2009244799B2 (en) 2014-11-20
JP2016172745A (ja) 2016-09-29
KR20110007242A (ko) 2011-01-21
CA2723558A1 (en) 2009-11-12

Similar Documents

Publication Publication Date Title
BRPI0908092A2 (pt) Edulcorante, método para preparar uma composição edulcorante, e, composição edulcorante
BR112012000623A2 (pt) composição de emulsão estabilizada, método, e, método para preparar uma composição de emulsão estabilizada
BRPI0817727A2 (pt) composição de graxa lubrificante, e, método para preparar uma composição de graxa
BRPI1010775A2 (pt) composição, método para preparar uma composição, e, uso de uma composição.
BRPI0909691A8 (pt) composto, método para preparar um composto, e, composição farmacêutica
BRPI0921718A2 (pt) composição, método para produzir uma composição, e, artigo moldado
BRPI0906906A2 (pt) Método para preparar um composto e composto
BRPI0819946A2 (pt) Composição de matéria e método para preparar uma composição tensoativa
BRPI0919575A2 (pt) método, e, composição
BRPI0918170A2 (pt) método, e, composição endurecível
BRPI1007561A2 (pt) método para revitalizar uma composição contendo betume, e, composição
BRPI0823277A2 (pt) Composição, e , método
BR112012002102A2 (pt) composição farmaceutica e metodo para preparar uma composição farmaceutica
BRPI0916787A2 (pt) artigo, e, método para fabricar um artigo
BRPI1015095A2 (pt) composição, processos para preparar uma composição e um material de poli-isocianurato , e, material de poli-isocianurato
BRPI0809573A8 (pt) composição, e, método
BR112014015042A2 (pt) composição farmacêutica, e, método para obter uma composição radiofarmacêutica
BR112012015100A2 (pt) composição de polímero modificado, artigo e método para produzir uma composição de polímero modificado
BRPI0910950A2 (pt) haste de perfuração, e, método para fabricar uma haste de perfuração
BRPI0820644A2 (pt) método de preparação de uma composição, e, composição
BRPI0913136A2 (pt) método para produzir uma peça e peça.
BRPI0823238A2 (pt) Composição, e, método
BRPI0720705A2 (pt) Método para preparar uma composição de espumação, e, composição de espumação
BRPI0917345A2 (pt) composição, e, método para produzir uma composição estabilizada.
BR112014014285A2 (pt) composição, e, método para fabricar uma composição

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]